Literature DB >> 18154446

Global analysis of genetic variation in SLCO1B1.

Marja K Pasanen1, Pertti J Neuvonen, Mikko Niemi.   

Abstract

INTRODUCTION: Organic anion transporting polypeptide 1B1 (OATP1B1), encoded by the SLCO1B1 gene, mediates the hepatic uptake of endogenous compounds and xenobiotics, including drugs. The aim of this study was to investigate the diversity of the SLCO1B1 gene at the global level.
MATERIALS AND METHODS: Distribution of SLCO1B1 alleles was determined in 941 individuals from 52 populations comprising Africa, the Middle East, Asia, Europe, Oceania and the Americas. DNA samples were genotyped at 12 variant sites spanning the entire gene by TaqMan 5 nuclease allelic discrimination assays.
RESULTS: The frequency of the low-activity c.521T>C variant varied markedly between populations. The lowest frequencies were observed in Oceania (0.0%; 95% CI: 0.0-6.4%) and sub-Saharan Africa (1.9%; 95% CI: 0.7-4.8%), and the highest frequencies observed in American native populations (24%; 95% CI: 18-32%) and Europe (18%; 95% CI: 14-23%). Moreover, the c.521C allele (r = 0.505, p < 0.001) and the *1B (c.388G-c.521T; r = -0.405, p = 0.006) and *15 (c.388G-c.521C; r = 0.510, p < 0.001) haplotype frequencies correlated significantly with latitude in the northern hemisphere. Overall, SLCO1B1 genetic distances correlated significantly with geographic distances between populations, assuming likely routes of human migration out of Africa via five waypoints (r = 0.235, p = 0.001). SLCO1B1 diversity was generally far greater within than between populations.
CONCLUSION: Functionally significant variants of SLCO1B1 are widely distributed and occur at high frequencies around the world. SLCO1B1 diversity is greater within than between populations, and genetic variation in SLCO1B1 is generally similar to that observed for other autosomal markers. However, selective pressure may have acted on SLCO1B1 during human dispersal favoring low-activity variants in the north.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18154446     DOI: 10.2217/14622416.9.1.19

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  57 in total

1.  Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method.

Authors:  Eleni Aklillu; Sabina Mugusi; Eliford Ngaimisi; Michael Marcus Hoffmann; Sonja König; Victoria Ziesenitz; Gerd Mikus; Walter Emil Haefeli; Johanna Weiss
Journal:  Eur J Clin Pharmacol       Date:  2011-06-01       Impact factor: 2.953

2.  Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.

Authors:  Laura B Ramsey; Gitte H Bruun; Wenjian Yang; Lisa R Treviño; Selina Vattathil; Paul Scheet; Cheng Cheng; Gary L Rosner; Kathleen M Giacomini; Yiping Fan; Alex Sparreboom; Torben S Mikkelsen; Thomas J Corydon; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Genome Res       Date:  2011-12-06       Impact factor: 9.043

3.  Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs.

Authors:  Evita van de Steeg; Els Wagenaar; Cornelia M M van der Kruijssen; Johanna E C Burggraaff; Dirk R de Waart; Ronald P J Oude Elferink; Kathryn E Kenworthy; Alfred H Schinkel
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

Review 4.  Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.

Authors:  Tristan M Sissung; Sarah M Troutman; Tessa J Campbell; Heather M Pressler; Hyeyoung Sung; Susan E Bates; William D Figg
Journal:  Discov Med       Date:  2012-01       Impact factor: 2.970

Review 5.  Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.

Authors:  John D Clarke; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-01-27       Impact factor: 4.481

Review 6.  Prediction of hepatic clearance in human from in vitro data for successful drug development.

Authors:  Masato Chiba; Yasuyuki Ishii; Yuichi Sugiyama
Journal:  AAPS J       Date:  2009-04-30       Impact factor: 4.009

7.  Genome-wide association meta-analysis for total serum bilirubin levels.

Authors:  Andrew D Johnson; Maryam Kavousi; Albert V Smith; Ming-Huei Chen; Abbas Dehghan; Thor Aspelund; Jing-Ping Lin; Cornelia M van Duijn; Tamara B Harris; L Adrienne Cupples; Andre G Uitterlinden; Lenore Launer; Albert Hofman; Fernando Rivadeneira; Bruno Stricker; Qiong Yang; Christopher J O'Donnell; Vilmundur Gudnason; Jacqueline C Witteman
Journal:  Hum Mol Genet       Date:  2009-05-04       Impact factor: 6.150

8.  The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients.

Authors:  Xiang-Ping Li; Ji-Ye Yin; Ying Wang; Hui He; Xi Li; Wei-Jing Gong; Juan Chen; Chen-Yue Qian; Yi Zheng; Fang Li; Tao Yin; Zhi-Cheng Gong; Bo-Ting Zhou; Yu Zhang; Ling Xiao; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Tumour Biol       Date:  2014-05-23

9.  HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.

Authors:  Ruben C Hartkoorn; Wai San Kwan; Victoria Shallcross; Ammara Chaikan; Neill Liptrott; Deirdre Egan; Enrique Salcedo Sora; Chloë E James; Sara Gibbons; Pat G Bray; David J Back; Saye H Khoo; Andrew Owen
Journal:  Pharmacogenet Genomics       Date:  2010-02       Impact factor: 2.089

10.  The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.

Authors:  Annikka Kalliokoski; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi
Journal:  Br J Clin Pharmacol       Date:  2008-09-23       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.